About

Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.

LDN BOS SFO
Watch The Abingworth Edge

ABINGWORTH'S TRANSATLANTIC REACH

With offices in the world's key biotech centres, we support entrepreneurs in both the US and Europe.

We benefit from our transatlantic approach through a broader understanding of competitive geographies, expertise in many different capital markets, access to a larger pool of management talent and wider scientific networks.

Abingworth Clinical Co-Development 2016 Abingworth Bioventures VI 2012 Abingworth Bioventures V 2008 Abingworth Bioventures V 2007 Abingworth BioEquities 2005 Abingworth Bioventures IV 2003 Abingworth Bioventures IIa 2002 Abingworth Bioventures IV 2003 Abingworth Bioventures IIa 2002 Abingworth Bioventures III 2001 Abingworth Bioventures II 1997 Abingworth Bioventures 1993 Biotechnology Venture Fund 1987
2016 Abingworth Clinical Co-Development
2012 Abingworth Bioventures VI
2008 Abingworth Bioventures V Growth Equity
2007 Abingworth Bioventures V
2005 Abingworth BioEquities
2003 Abingworth Bioventures IV
2002 Abingworth Bioventures IIa
2001 Abingworth Bioventures III
1997 Abingworth Bioventures II
1993 Abingworth Bioventures
1987 Biotechnology Venture Fund

11 LIFE SCIENCE FUNDS

Abingworth has raised 11 funds dedicated to investing in life sciences and healthcare. Our most recent, Abingworth Clinical Co-Development Fund and Abingworth Bioventures VI, raised $108 million and £225 million ($375 million) respectively and are actively investing.

Venture Funds

Our venture funds invest across our broad strategic areas of venture capital, clinical co-development, VIPEs and public markets. They focus primarily on private companies but invest a percentage of their value in public companies.

Public Market Fund

Abingworth BioEquities (ABE) is dedicated solely to investing in public life science companies. Employing a long-only investment approach, our open-ended fund invests worldwide in public small-cap life sciences companies taking leadership positions in syndicated deals, participating in private placements as well as buying and selling shares in the open market.

List all funds
Close

Abingworth Films

Currently Watching
Wilson Therapeutics
Currently Watching
Verona Pharma
Currently Watching
SutroVax
Currently Watching
SFJ Pharmaceuticals II
Currently Watching
GenSight
Currently Watching
CRISPR Therapeutics